Comparison between the original biological agents and their biosimilars authorized in portugal

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Covilhã, Portugal)
  • Co-author(s): Manuel Morgado: Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
    Andreia Gonçalves: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Joana Alves: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Marta Fernandes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Miguel Vaz: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Sara Fernandes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
    Sandra Morgado: Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal
  • Abstract:

    Background

    Biological agents are widely used in several pathologies such as, rheumatic and blood diseases. They are not often used as first line treatment due to its high costs. The development of biosimilars allow earlier access to this therapy due to their reduced price. Biosimilars are medicines with the same biological substances with similar

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login